
Please try another search
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. The company was founded in 2003 and is based in Hangzhou, China.
Name | Age | Since | Title |
---|---|---|---|
Xinqi Huang | 52 | 2021 | Independent Director |
Rong Wang | 61 | 2022 | Shareholder Supervisor |
Lieming Ding | 62 | 2013 | Founder, Chairman of the Board, CEO & GM |
Wei Wang | 58 | 2019 | Independent Director |
Tian Xu | 63 | 2022 | Director |
Zhihua Yu | 58 | 2019 | Director |
Cai Jiangnan | 68 | 2019 | Independent Director |
Jiajia Xiao | 42 | 2022 | Independent Director |
Yangnan Zhang | 54 | 2019 | Chairman of the Supervisory Board & Senior Director of Project Declaration |
Fei Wu | 48 | - | Supervisor & Senior Director of Internal Control Affairs |
Jianxun Fan | 54 | 2017 | VP, CFO & Director |
Jia Tong | 48 | 2013 | Chief Administrative Officer & Director |
Jiang Wan | 57 | 2013 | Senior VP, COO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review